Tag: antipsychotic discontinuation
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
There are a number of well-recognised problems with this sort of study and we should be very cautious about accepting its conclusions at face value. The main problem is that it is an ‘observational’ study, not a randomised controlled trial, and these analyses can be seriously misleading.
The authors conclude that the risk of treatment failure or relapse after discontinuation of antipsychotics does not decrease during the first eight years of illness, and that long-term antipsychotic treatment is associated with increased survival. This is a sobering finding and the paper warrants careful review.
A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.
This week Live & Learn launched a research study on the experience of people labeled with mental disorders who have tried to stop taking psychiatric medications. This project -- the Psychiatric Medication Discontinuation/Reduction (PMDR) Study -- aims to understand the process of coming off psychiatric medications in order to better support those who choose to do so. The study seeks to answer the question: What helps people stop their psychiatric medications? What gets in the way of stopping?
The writings of Pies and his colleagues, I believe, provide a compelling case study of cognitive dissonance. Cognitive dissonance arises when people are presented with information that creates conflicted psychological states, challenging some belief they hold dear, and people typically resolve dissonant states by sifting through information in ways that protect their self-esteem and their financial interests. It is easy to see that process operating here.
For a long time I have felt that there just isn’t a good enough and long enough study on the pros and cons of long-term antipsychotic treatment versus reduction and discontinuation in people who have psychotic disorders, including those who are classified as having schizophrenia. Moreover, there are increasing reasons to be worried about the effects of long-term treatment with antipsychotics. I put this case to the UK’s National Institute of Health Research recently, and proposed that they fund a trial to assess the long-term outcomes of a gradual programme of antipsychotic reduction compared with standard ‘maintenance treatment.’ The NIHR agreed that this was an important issue, and that a new trial was urgently needed. The RADAR (Research into Antipsychotic Discontinuation And Reduction) study officially started in January 2016.